Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Détails

ID Serval
serval:BIB_97656BB59CC8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.
Périodique
Blood
Auteur⸱e⸱s
Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T.H., Chang A., Coukos G., Liu R., Zou W.
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Statut éditorial
Publié
Date de publication
2009
Volume
114
Numéro
6
Pages
1141-1149
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Th17 cells play an active role in autoimmune diseases. However, the nature of Th17 cells is poorly understood in cancer patients. We studied Th17 cells, the associated mechanisms, and clinical significance in 201 ovarian cancer patients. Tumor-infiltrating Th17 cells exhibit a polyfunctional effector T-cell phenotype, are positively associated with effector cells, and are negatively associated with tumor-infiltrating regulatory T cells. Tumor-associated macrophages promote Th17 cells through interleukin-1beta (IL-1beta), whereas tumor-infiltrating regulatory T cells inhibit Th17 cells through an adenosinergic pathway. Furthermore, through synergistic action between IL-17 and interferon-gamma, Th17 cells stimulate CXCL9 and CXCL10 production to recruit effector T cells to the tumor microenvironment. The levels of CXCL9 and CXCL10 are associated with tumor-infiltrating effector T cells. The levels of tumor-infiltrating Th17 cells and the levels of ascites IL-17 are reduced in more advanced diseases and positively predict patient outcome. Altogether, Th17 cells may contribute to protective human tumor immunity through inducing Th1-type chemokines and recruiting effector cells to the tumor microenvironment. Inhibition of Th17 cells represents a novel immune evasion mechanism. This study thus provides scientific and clinical rationale for developing novel immune-boosting strategies based on promoting the Th17 cell population in cancer patients.
Mots-clé
Adult, Aged, Chemokine CXCL10/immunology, Chemokine CXCL9/immunology, Female, Humans, Immunotherapy, Interleukin-17/immunology, Interleukin-1beta/immunology, Macrophages/immunology, Macrophages/pathology, Middle Aged, Ovarian Neoplasms/immunology, Ovarian Neoplasms/pathology, T-Lymphocytes, Helper-Inducer/immunology, T-Lymphocytes, Helper-Inducer/pathology
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/10/2014 11:43
Dernière modification de la notice
20/08/2019 14:59
Données d'usage